Heron Therapeutics, Inc. announced on 10 August 2016 that the US Food and Drug Administration (FDA) has approved extended-release granisetron injection (SUSTOL®), a serotonin-3 (5-HT3) receptor antagonist indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.
Read more here.
No comments:
Post a Comment